Niki BioSolutions Completes Merger & Domestication; Files Interim Financials

What Happened
Niki BioSolutions, Inc. (formerly Aptorum Group Limited) announced it consummated the merger with DiamiR Biosciences pursuant to a Merger Agreement dated July 14, 2025, with the closing and domestication occurring on July 20, 2026. Immediately prior to closing, Aptorum effected a continuation (domestication) from a Cayman Islands company to a Delaware corporation; following the domestication, Merger Sub merged into DiamiR with DiamiR continuing as a wholly‑owned subsidiary of Aptorum/Niki BioSolutions. Because the domestication changed the company from a foreign private issuer to a U.S. domestic issuer, the company furnished unaudited interim condensed consolidated financial statements and related operating and financial review for the six months ended June 30, 2026 (and comparative periods).

Key Details

• Merger Agreement dated July 14, 2025; closing and domestication took place on July 20, 2026.
• Aptorum transferred by continuation to Delaware under DGCL Section 388 and Cayman Islands Companies Act Section 206.
• DiamiR now a wholly‑owned subsidiary of Aptorum/Niki BioSolutions after Merger Sub merged into DiamiR.
• The company furnished: unaudited interim condensed consolidated financial statements as of June 30, 2026 and Dec 31, 2025 and for the six months ended June 30, 2026 and 2025; an operating and financial review; and Inline XBRL cover page data—these were incorporated by reference into the company’s Form S‑8 (333‑281028) and Form F‑3 (333‑292793) registration statements.

Why It Matters
The filing confirms a completed corporate reorganization (domestication) and merger that change the company’s legal domicile and reporting status—moving from a foreign private issuer to a U.S. domestic issuer—which brings different SEC filing obligations. Investors should note the company has furnished interim financial statements to comply with domestic reporting requirements and incorporated them into its registration statements; this is procedural and does not, in this 8‑K, report operational results beyond the provided interim statements. Review those included interim financials and the operating and financial review for specifics on recent financial performance.